Aurinia Pharmaceuticals (AUPH) closed FY 2025 with Q4 revenue of US$77.1 million and basic EPS of US$1.60, alongside trailing twelve month EPS of US$2.14 on revenue of US$283.1 million. This frames a very strong headline earnings story. Over the past few quarters, the company has seen revenue move from US$59.9 million in Q4 2024 to US$77.1 million in Q4 2025, while quarterly EPS shifted from roughly breakeven at US$0.01 to US$1.60, with trailing twelve month net income reaching US$287.2 million. For investors, the key question now is how durable these higher profit margins are and what they imply for the quality of earnings going forward.

See our full analysis for Aurinia Pharmaceuticals.

With the headline numbers set, the next step is to line these results up against the main narratives around Aurinia, highlighting where the recent margin profile backs the story and where it raises fresh questions.

TTM net income now slightly ahead of revenue

• On a trailing twelve month basis, Aurinia reported net income of US$287.2 million on revenue of US$283.1 million, which means reported profit is slightly larger than sales over the same period.
• What stands out for the bullish narrative is how this very high reported profitability sits alongside claims of stronger LUPKYNIS adoption and cost discipline:
  • Bulls point to three year efficacy data and updated treatment guidelines as drivers of revenue momentum. The trailing revenue line at US$283.1 million gives that story some support, even though part of the earnings jump is flagged as non cash.
  • At the same time, the sharp step up from quarterly net income of US$1.4 million in Q4 2024 to US$210.8 million in Q4 2025 is so extreme that it invites the question of how much is repeatable operating profit versus one off or accounting driven items that bullish investors need to separate out.

Some investors see this earnings profile as the start of a stronger long term story, while others are more cautious about how much of it is sustainable.

🐂 Aurinia Pharmaceuticals Bull Case

Low 6.4x P/E versus high growth backdrop

• The shares trade on a P/E of 6.4x against a current price of US$13.97, while revenue is described as forecast to grow about 11.7% per year and TTM EPS sits at US$2.14.
• Bears highlight that even this low multiple may be justified if the quality of those earnings is weaker than it looks and if profits ease back from here:
  • The risk summary flags that a large portion of earnings is non cash, so the gap between US$287.2 million of TTM net income and the revenue line can challenge the idea that the stock simply looks cheap on headline EPS.
  • Analyst models pointing to roughly 5.1% annual earnings declines over the next three years run against the very strong trailing profit picture, which supports the bearish view that the current 6.4x P/E might already be factoring in some of this pressure.

For you as an investor, the tension between a low P/E and earnings forecasts is where a lot of the debate is happening.

🐻 Aurinia Pharmaceuticals Bear Case

DCF fair value far above current price

• The DCF fair value provided is US$41.93 per share versus the current share price of US$13.97, while the only allowed analyst price target reference here is US$16.67, so both reference points sit above where the stock trades today.
• Consensus narrative views this gap through the lens of both opportunities and risks, and the recent financials give you data for each side:
  • On the opportunity side, analysts expect revenue to grow 14.1% per year with profit margins moving from 23.3% to 36.6%, and TTM margins are already described as 2.4 percentage points higher than a year ago. This lines up with a story of improving economics.
  • On the risk side, the same consensus flags that earnings are expected to be around US$141.3 million by 2028, well below the current TTM net income of US$287.2 million. This signals that the recent profitability spike is not being treated as a permanent baseline in those models.

That mix of a higher DCF fair value and more cautious earnings forecasts is why it helps to separate one off strength from what you think Aurinia can produce year in, year out.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Aurinia Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both bullish and bearish cases on the table, this is the moment to review the numbers yourself and move quickly to shape your own view, starting with 4 key rewards and 2 important warning signs.

See What Else Is Out There

The big question hanging over Aurinia is whether current earnings, which rely heavily on non cash items and sit above revenue, can really hold over time.

If you want ideas where profits and cash flows may be more closely aligned, check out our 77 resilient stocks with low risk scores right now and compare how those companies handle earnings quality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.